Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gibbs

Showing results (371-380 of 427) with videos related to

Pageof 43
Sort By:
Clinical Colorectal Cancer|March 18, 2021
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I InhibitorsKoji Ando, Al Ozonoff, Shin-Yin Lee, et al.
Journal of the National Cancer Institute|April 10, 2021
Genomic Risk Score for Melanoma in a Prospective Study of Older IndividualsAndrew Bakshi, Mabel Yan, Moeen Riaz, et al.
Cell Death & Disease|March 1, 2024
BCL-X<sub>L</sub> inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF<sup>V600E</sup> colorectal cancerLaura J Jenkins, Ian Y Luk, Fiona Chionh, et al.
Cancer Science|November 12, 2022
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancerTakayuki Yoshino, Thierry Andre, Tae Won Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2020
Assessing aneuploidy with repetitive element sequencingChristopher Douville, Joshua D Cohen, Janine Ptak, et al.
JAMA Oncology|October 18, 2019
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon CancerJeanne Tie, Joshua D Cohen, Yuxuan Wang, et al.
The American Journal of Gastroenterology|September 18, 2013
Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutationsDmitri Mouradov, Enric Domingo, Peter Gibbs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2013
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17Christos S Karapetis, Derek Jonker, Manijeh Daneshmand, et al.
Journal of Gastrointestinal Oncology|November 12, 2025
Effects of current smoking on treatment outcomes in metastatic and locally advanced pancreatic carcinoma: a retrospective cohort study using the international PURPLE pancreas cancer registryFaisal Hayat, Simon Chiu, Ashleigh Stuart, et al.
British Journal of Cancer|August 26, 2015
Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancerRobert N Jorissen, Michael Christie, Dmitri Mouradov, et al.
Pageof 43

Showing results (371-380 of 427) with videos related to

Sort By:
Pageof 43
Clinical Colorectal Cancer|March 18, 2021
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I InhibitorsKoji Ando, Al Ozonoff, Shin-Yin Lee, et al.
Journal of the National Cancer Institute|April 10, 2021
Genomic Risk Score for Melanoma in a Prospective Study of Older IndividualsAndrew Bakshi, Mabel Yan, Moeen Riaz, et al.
Cell Death & Disease|March 1, 2024
BCL-X<sub>L</sub> inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAF<sup>V600E</sup> colorectal cancerLaura J Jenkins, Ian Y Luk, Fiona Chionh, et al.
Cancer Science|November 12, 2022
Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancerTakayuki Yoshino, Thierry Andre, Tae Won Kim, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 21, 2020
Assessing aneuploidy with repetitive element sequencingChristopher Douville, Joshua D Cohen, Janine Ptak, et al.
JAMA Oncology|October 18, 2019
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon CancerJeanne Tie, Joshua D Cohen, Yuxuan Wang, et al.
The American Journal of Gastroenterology|September 18, 2013
Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutationsDmitri Mouradov, Enric Domingo, Peter Gibbs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2013
PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17Christos S Karapetis, Derek Jonker, Manijeh Daneshmand, et al.
Journal of Gastrointestinal Oncology|November 12, 2025
Effects of current smoking on treatment outcomes in metastatic and locally advanced pancreatic carcinoma: a retrospective cohort study using the international PURPLE pancreas cancer registryFaisal Hayat, Simon Chiu, Ashleigh Stuart, et al.
British Journal of Cancer|August 26, 2015
Wild-type APC predicts poor prognosis in microsatellite-stable proximal colon cancerRobert N Jorissen, Michael Christie, Dmitri Mouradov, et al.
Pageof 43